Indirect Trial Comparison Suggests Retifanlimab Edges Out Avelumab in Metastatic Merkel Cell Carcinoma
A matching-adjusted indirect comparison of two landmark trials suggests retifanlimab significantly prolongs progression-free survival compared with avelumab in metastatic Merkel ...
